Akums announces entry into nutraceutical gummies segment

Expanding its R&D and manufacturing facility to introduce next gen gummies

New Delhi-based contract development and manufacturing organisation (CDMO) Akums Drugs and Pharmaceutical has announced entry into the nutraceutical gummies segment with a series of novel formulations for wellness and common ailments.

This initiative seeks to cater to a host of conditions, that comes as a solution for adults, paediatrics and geriatric population who are looking for an alternative to conventional dosage forms like tablets, capsules, syrup etc.  who no longer find pills/capsules/syrups palatable or convenient.

Sandeep Jain, Jt. Managing Director of Akums said, “The production of our new gummies formulations is done at our state-of-the-art Maxcure Nutravedics plant, a subsidiary of Akums, with proven expertise in nutraceutical, ayurvedic, and health supplements.”

The global gummies market is expected to grow at a CAGR of 7.3% between 2021 and 2028, with current valuations of the segment at around $3.4 to $8 billion. Akums says its venture in gummies manufacturing is a game-changer with all possible combinations of flavours and textures, such as natural, natural identical & artificial colours; pectin, gelatin, and sugar based; low sugar, no added sugar, etc.

Within this year, Akums will be expanding its R&D and manufacturing facility to introduce next gen gummies that will be the first time in the world thus supporting the differentiated requirements of diverse consumers.

Read Previous

India’s first Turkish ice cream brand Twisting Scoops further expands to Mumbai

Read Next

Life Health Foods launches oat milk-based beverage in India

Leave a Reply